Lineage Cell Therapeutics Forecast, price target & analysts
Lineage Cell Therapeutics Target price 2025 - Analyst rating & recommendation
Lineage Cell Therapeutics Classifications & Recommendation:
Lineage Cell Therapeutics Price Target
| Target Price | $3.06 |
| Price | $1.70 |
| Potential |
80.00%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Lineage Cell Therapeutics 2026 .
The average Lineage Cell Therapeutics target price is $3.06.
This is
80.00%
register free of charge
$9.45
455.88%
register free of charge
$2.02
18.82%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Lineage Cell Therapeutics to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Lineage Cell Therapeutics stock has an average upside potential 2026 of
80.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.50 | 8.81 |
| 6.15% | 7.28% | |
| EBITDA Margin | -225.89% | -433.57% |
| 17.91% | 91.93% | |
| Net Margin | -195.89% | -517.55% |
| 18.42% | 164.20% |
9 Analysts have issued a sales forecast Lineage Cell Therapeutics 2025 . The average Lineage Cell Therapeutics sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Lineage Cell Therapeutics EBITDA forecast 2025. The average Lineage Cell Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Lineage Cell Therapeutics Analysts have issued a net profit forecast 2025. The average Lineage Cell Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.09 | -0.20 |
| 25.00% | 122.22% | |
| P/E | negative | |
| EV/Sales | 39.28 |
9 Analysts have issued a Lineage Cell Therapeutics forecast for earnings per share. The average Lineage Cell Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Lineage Cell Therapeutics...
Current Lineage Cell Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 27 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jun 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 27 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jun 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 23 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
